Pulse steroid therapy in rheumatoid arthritis SIR, After a decade of the use of intravenous 'pulse' megadose corticosteroids in rheumatoid arthritis we now have a controlled study that shows there is no difference in effect from a similar 'pulse' given orally.' Although the authors pointed out that this obviates the need for hospital admission and thus makes fewer demands on medical and nursing resources, they did not emphasise the financial savings, which are considerable. The average bed cost a day was $429*44 in 1987 at a large Australian teaching hospital similar to the authors' institution.2 Methylprednisolone 1-0 g for intravenous use costs $103, compared with $8-26 for 41x25 mg tablets of prednisolone.
The authors have shown that 'pulse' megadose corticosteroid is followed by improvement of rheumatoid arthritis, maintained for 24 weeks. Apart from mentioning that nine of the 24 patients were concurrently receiving new disease suppressive agents (presumably slow acting antirheumatic drugs or cytotoxic agents), however, they made no other comment on this aspect of their study. Perhaps they have refrained from doing so as there was no placebo treated control group for comparison.
I would think it worthwhile if the authors addressed this point in these columns lest we be left with the impression that the improvement related solely to the 'pulse' corticosteroid given. For instance: did the above mentioned nine patients achieve remission; were others already taking or subsequently to begin taking disease suppressive drugs; were any taking oral corticosteroids already, or was treatment started with them during the 24 week follow up period?
6 Waratah Avenue, JOHN WEBB Biggera Waters, Qld 4216, Australia improvement of these patients, it is probable that their clinical improvement was sustained by the administration of these agents. The study was not designed to answer this question, which has been addressed in another publication' and is the subject of a recently completed clinical trial by the authors. Finally, as shown in Table 1 of our paper2 seven patients in each group were already receiving disease suppressing agents at the time of study. All treatment was continued unaltered for the duration of the trial and no oral or intra-articular steroids were administered during the 24 week follow up period. No patient was receiving oral corticosteroids at the time of entry into the study. 
